LC–MS/MS profiling, network pharmacology, and hERG liability docking of Haliclona caerulea metabolites as putative cardioprotective candidates

Abstract

Introduction: Cardiovascular disease is a leading cause of death worldwide; post-infarction injury involves oxidative stress and inflammation. Cardioprotective leads from marine sponges need early screening for cardiac ion-channel liability, because block of the human ether-à-go-go-related gene (hERG) channel prolongs the QT interval and may provoke fatal arrhythmia. For Indonesian Haliclona caerulea, neither the metabolite profile nor its cardiac target space has been reported.


Objectives: To profile metabolites of the n-hexane fraction of H. caerulea, predict their myocardial infarction targets, and screen them for hERG liability as a safety filter, not a therapeutic target.


Methods: The fraction was analyzed by untargeted LC–MS/MS and metabolites putatively annotated. Drug-likeness and toxicity were predicted with MolSoft, SwissADME, and ADMETlab 3.0. Candidates were docked into the hERG pore (PDB 8ZYP), benchmarked by re-docking E-4031. Targets came from SwissTargetPrediction, TargetNet, and SEA; disease genes from GeneCards.


Results: All seven metabolites met drug-likeness criteria and returned low ligand-based probabilities (< 0.7) for hERG inhibition, mutagenicity, and carcinogenicity. Docking nevertheless placed neopetrocyclamine A (–11.03 kcal/mol) and adociasulfate 6 (–10.04 kcal/mol) at the E-4031 site with affinities exceeding the blocker, contradicting that result. Network analysis identified 132 shared and ten hub genes.


Conclusion: The target network supports putative cardioprotective interest, whereas docking flags the two strongest pore binders as carrying an unresolved proarrhythmic liability requiring experimental validation.

References

[1] Valaitienė J, Laučytė-Cibulskienė A. Oxidative stress and its biomarkers in cardiovascular diseases. Artery Res. 2024;30: 1–12. https://doi.org/10.1007/s44200-024-00062-8

[2] Zhang Z, Guo J. Deciphering oxidative stress in cardiovascular disease progression: a blueprint for mechanistic understanding and therapeutic innovation. Antioxidants (Basel). 2024;14: 38. https://doi.org/10.3390/antiox14010038

[3] Karimpoor M, Kamrani E, Yousefzadi M, Nazemi M. Antibacterial and antioxidant potential of Haliclona caerulea extracts from Tidal Island Larak, Persian Gulf. Modares J Biotechnol. 2018;9: 347–353.

[4] Varijakzhan D, Loh JY, Yap WS, Yusoff K, Seboussi R, Lim SHE, et al. Bioactive compounds from marine sponges: fundamentals and applications. Mar Drugs. 2021;19: 246. https://doi.org/10.3390/md19050246

[5] Mehbub MF, Yang Q, Cheng Y, Franco CMM, Zhang W. Marine sponge-derived natural products: trends and opportunities for the decade of 2011–2020. Front Mar Sci. 2024;11: 1462825. https://doi.org/10.3389/fmars.2024.1462825

[6] Furutani K. Facilitation of hERG activation by its blocker: a mechanism to reduce drug-induced proarrhythmic risk. Int J Mol Sci. 2023;24: 16261. https://doi.org/10.3390/ijms242216261

[7] Olivia Y, Park H, Ariyadi, Qauli AI, Fuadah YN, Marcellinus A, et al. Incorporating inter-individual variability to improve the reliability of predicted outcomes in in silico cardiac safety assessment. Toxicol Appl Pharmacol. 2026;511: 117831. https://doi.org/10.1016/j.taap.2026.117831

[8] Fu L, Shi S, Yi J, Wang N, He Y, Wu Z, et al. ADMETlab 3.0: an updated comprehensive online ADMET prediction platform enhanced with broader coverage, improved performance, API functionality and decision support. Nucleic Acids Res. 2024;52: W422–W431. https://doi.org/10.1093/nar/gkae236

[9] Schymanski EL, Jeon J, Gulde R, Fenner K, Ruff M, Singer HP, et al. Identifying small molecules via high resolution mass spectrometry: communicating confidence. Environ Sci Technol. 2014;48: 2097–2098. https://doi.org/10.1021/es5002105

[10] Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47: W357–W364. https://doi.org/10.1093/nar/gkz382

[11] Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51: D638–D646. https://doi.org/10.1093/nar/gkac1000

[12] Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem. 1996;17: 490–519. https://doi.org/10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P

[13] Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7: 42717. https://doi.org/10.1038/srep42717

[14] Miyashita Y, Moriya T, Kato T, Kawasaki M, Yasuda S, Adachi N, et al. Improved higher resolution cryo-EM structures reveal the binding modes of hERG channel inhibitors. Structure. 2024;32: 1926–1935.e3. https://doi.org/10.1016/j.str.2024.08.021

[15] Xue T, Wang S, Zhu X, Luo J, Zhu R, Li H, et al. Protective mechanisms of sirtuin family in myocardial ischemia-reperfusion injury and translational therapeutic perspectives. Mol Biol Rep. 2026;53: 1. https://doi.org/10.1007/s11033-026-12521-3

[16] Zhang X, Yang L, Feng K, Zhang H, Chen Y, Li W, et al. Shuxuening injection improves myocardial injury after myocardial infarction by regulating macrophage polarization via the TLR4/NF-κB and PI3K/Akt signaling pathways. Phytomedicine. 2025;138: 156418. https://doi.org/10.1016/j.phymed.2025.156418

[17] Helliwell MV, Zhang Y, El Harchi A, Dempsey CE, Hancox JC. Inhibition of the hERG potassium channel by a methanesulphonate-free E-4031 analogue. Pharmaceuticals (Basel). 2023;16: 1204. https://doi.org/10.3390/ph16091204
Published
2026-10-23
How to Cite
NADIAH, Syaadatun et al. LC–MS/MS profiling, network pharmacology, and hERG liability docking of Haliclona caerulea metabolites as putative cardioprotective candidates. Acta Pharmaciae Indonesia : Acta Pharm Indo, [S.l.], v. 14, n. 1, p. 18165, oct. 2026. ISSN 2621-4520. Available at: <https://jos.unsoed.ac.id/index.php/api/article/view/18165>. Date accessed: 18 nov. 2026. doi: https://doi.org/10.20884/1.api.2026.14.1.18165.